Recent updates on CAR T clinical trials for multiple myeloma

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Multiple myeloma (MM) treatments, including proteasome inhibitors and monoclonal antibodies, have improved outcomes but relapse remains common.
• Refractory/relapsed (RR) MM patients have limited therapeutic options.
• Chimeric antigen receptor (CAR) T-cell therapy is an emerging treatment modality for hematologic malignancies.

Purpose of the Study:

• To review recent advancements in CAR T-cell clinical trials for multiple myeloma.
• To summarize ongoing research and development of CAR T-cell therapies targeting various antigens in RRMM.

Main Methods:

• Review of ongoing clinical trials for CAR T-cell therapy in multiple myeloma.
• Analysis of CAR T-cell strategies targeting B cell maturation antigen (BCMA), CD138, CS1 glycoprotein antigen (SLAMF7), light chains, and CD19.
• Inclusion of studies on dual-target CAR T-cells and combination therapies.

Main Results:

• CAR T-cells targeting BCMA, CD138, SLAMF7, and light chains are under active investigation for RRMM.
• CD19-targeted CAR T-cells combined with autologous stem cell transplantation demonstrate activity in RRMM.
• Dual-target CAR T-cells are being evaluated in clinical trials for RRMM.

Conclusions:

• CAR T-cell therapy represents a promising frontier in the treatment of refractory/relapsed multiple myeloma.
• Ongoing clinical trials are exploring novel CAR T-cell targets and strategies to overcome treatment resistance and improve patient outcomes in MM.
• Further research and clinical evaluation are essential to establish the full potential of CAR T-cells in MM management.